The CLSN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLSN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CLSN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CLSN Detailed Price Forecast - CNN Money||View CLSN Detailed Summary - Google Finance|
|View CLSN Detailed Summary - Yahoo! Finance||View CLSN Stock Research & Analysis - Zacks.com|
|View CLSN Trends & Analysis - Trade-Ideas||View CLSN Major Holders - Barrons|
|View CLSN Call Transcripts - NASDAQ||View CLSN Breaking News & Analysis - Seeking Alpha|
|View CLSN Annual Report - CompanySpotlight.com||View CLSN OTC Short Report - OTCShortReport.com|
|View CLSN Fundamentals - TradeKing||View CLSN SEC Filings - Bar Chart|
|View Historical Prices for CLSN - The WSJ||View Performance/Total Return for CLSN - Morningstar|
|View the Analyst Estimates for CLSN - MarketWatch||View the Earnings History for CLSN - CNBC|
|View the CLSN Earnings - StockMarketWatch||View CLSN Buy or Sell Recommendations - MacroAxis|
|View the CLSN Bullish Patterns - American Bulls||View CLSN Short Pain Metrics - ShortPainBot.com|
|View CLSN Stock Mentions - StockTwits||View CLSN Stock Mentions - PennyStockTweets|
|View CLSN Stock Mentions - Twitter||View CLSN Investment Forum News - Investor Hub|
|View CLSN Stock Mentions - Yahoo! Message Board||View CLSN Stock Mentions - Seeking Alpha|
|View Insider Transactions for CLSN - SECform4.com||View Insider Transactions for CLSN - Insider Cow|
|View CLSN Major Holdings Summary - CNBC||View Insider Disclosure for CLSN - OTC Markets|
|View Insider Transactions for CLSN - Yahoo! Finance||View Institutional Holdings for CLSN - NASDAQ|
|View CLSN Stock Insight & Charts - FinViz.com||View CLSN Investment Charts - StockCharts.com|
|View CLSN Stock Overview & Charts - BarChart||View CLSN User Generated Charts - Trading View|
Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations
Posted on Monday September 17, 2018
Celsion Corporation (CLSN), an oncology drug development company, today announced the appointment of Marianne Lambertson as Vice President of Communications and Investor Relations effective September 17, 2018. Ms. Lambertson most recently held the position of Vice President, Corporate Communications, Investor Relations/Public Relations at Verastem Oncology, a development-stage biopharmaceutical company.
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Posted on Sunday September 16, 2018
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients
Posted on Thursday September 06, 2018
Celsion Corporation (CLSN), an oncology drug development company, today announced it has begun dosing patients in the recently initiated OVATION II Study, the Company's randomized, Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer as an adjuvant to chemotherapy current standard of care. GEN-1, designed using Celsion's proprietary TheraPlas platform technology, is an interleukin-12 (IL-12) DNA plasmid vector encased in a non-viral nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. "In previous studies, GEN-1 was shown to be well tolerated at doses up to 79 mg/m2 with meaningful, dose-dependent, pro-immune clinical activity,” said Dr. Nicholas Borys, Celsion's senior vice president and chief medical officer. “The overall median progression-free survival (PFS) in the first OVATION Study recently reached 24 months among patients treated per protocol.
Celsion Announces Enrollment Completion for Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Posted on Wednesday September 05, 2018
Celsion Corporation (CLSN), an oncology drug development company, today announced that it has reached its enrollment objective of 550 patients in the Company's pivotal, Phase III OPTIMA Study, a multinational, randomized, double-blind, placebo-controlled clinical trial of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of patients with hepatocellular carcinoma (HCC), also known as primary liver cancer. The OPTIMA Study's design and statistical plan incorporates two pre-planned interim efficacy analyses by the study’s Data Monitoring Committee (DMC), and the first interim analysis is expected to occur in the first half of 2019.